---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037575"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:50:33.046830+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PAVmed subsidiary Lucid Diagnostics raises $5M via Series A-1 Convertible Preferred Stock

## Summary
- Lucid Diagnostics, majority-owned PAVmed sub, sold 5,000 shares of newly designated Series A-1 Convertible Preferred at $1,000/share.
- Gross proceeds of $5.0 million from accredited investors; private placement closed October 18, 2023.
- Certificate of Designation and Registration Rights Agreement filed by Lucid on Form 8-K; terms incorporated by reference.

## SEC filing metadata
- accession: 0001493152-23-037575
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315223037575/0001493152-23-037575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315223037575/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037575
- JSON: https://secwatch.observer/filing/0001493152-23-037575.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037575.txt

## Key facts
- Material Agreements
  PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at aggregate gross proceeds to Lucid of $5.0 million (effective 2023-10-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: aggregate gross proceeds to Lucid of $5.0 million
  - Effective: 2023-10-17
  source text: Effective as of October 17, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 5,000 shares of newly designated Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to Lucid of $5.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315223037575/0001493152-23-037575-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.